Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.94 |
| ▸ | MAPT | P10636 | 8/20 | 0.94 |
| ▸ | NPC1 | O15118 | 7/20 | 0.94 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.94 |
| ▸ | MEN1 | O00255 | 2/20 | 0.94 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.94 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | GAA | P10253 | 3/20 | 0.54 |
| ▸ | PKM | P14618 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL220846 | 0.98 | RAB9A (0.97) | RAB9AMAPTNPC1ALDH1A1MEN1 | |
| Hydrochloric Acid SCHEMBL16653815 | 0.97 | RAB9A (1.00) | RAB9AMAPTNPC1ALDH1A1MEN1 | |
| Bromide SCHEMBL4038829 | 0.94 | RAB9A (0.83) | RAB9AMAPTNPC1ALDH1A1MEN1 | |
| SCHEMBL1136365 | 0.85 | ALDH1A1 (0.74) | RAB9AMAPTNPC1ALDH1A1MEN1 | |
| SCHEMBL14072172 | 0.85 | RAB9A (0.72) | RAB9AMAPTNPC1ALDH1A1MEN1 | |
| SCHEMBL14086070 | 0.83 | ALDH1A1 (0.70) | RAB9AMAPTNPC1ALDH1A1MEN1 | |
| SCHEMBL353584 | 0.82 | ALDH1A1 (0.69) | RAB9AMAPTNPC1ALDH1A1MEN1 | |
| SCHEMBL11184434 | 0.81 | MAPT (0.68) | RAB9AMAPTNPC1ALDH1A1MEN1 | |
| SCHEMBL7107465 | 0.81 | MAPT (0.68) | RAB9AMAPTNPC1ALDH1A1MEN1 | |
| SCHEMBL7107470 | 0.81 | MAPT (0.68) | RAB9AMAPTNPC1ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11274074-B2 | Pharmaceutical composition for ANO1 antagonist with anticancer activity | INDUSTRY-ACADEMIC COOPERATION FOUNDATION YONSEI UNIVERSITY (KR) | 2022-03-15 | — | — | US | disclosed |
| US-20200087250-A1 | PHARMACEUTICAL COMPOSITION FOR ANO1 ANTAGONIST WITH ANTICANCER ACTIVITY | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2020-03-19 | — | — | US | disclosed |
| US-9586916-B2 | Integrin antagonist conjugates for targeted delivery to cells expressing alpha-V-beta-3 | HOFFMANN-LA ROCHE INC. (US) | 2017-03-07 | — | — | US | disclosed |
| EP-2806899-B1 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING ALPHA-V-BETA-3 | HOFFMANN LA ROCHE (CH) | 2016-10-19 | — | — | EP | disclosed |
| US-20150038523-A1 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING ALPHA-V-BETA-3 | HOFFMANN-LA ROCHE INC. (US) | 2015-02-05 | — | — | US | disclosed |
| EP-2806899-A1 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING ALPHA-V-BETA-3 | F.HOFFMANN-LA ROCHE AG (CH) | 2014-12-03 | — | — | EP | disclosed |
| EP-1608365-B1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | R TECH UENO LTD (JP) | 2013-10-02 | — | — | EP | disclosed |
| WO-2013110578-A1 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING ALPHA-V-BETA-3 | F. HOFFMANN-LA ROCHE AG (CH) | 2013-08-01 | — | — | WO | disclosed |
| US-20100261760-A1 | EP2 Receptor Agonists | ASTERAND UK LIMITED (GB) | 2010-10-14 | — | — | US | disclosed |
| US-7803841-B2 | EP2 receptor agonists | ASTERAND UK LIMITED (GB) | 2010-09-28 | — | — | US | disclosed |
| US-5998470-A | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1999-12-07 | — | — | US | disclosed |
| WO-1999053039-A1 | TREATMENT OF PARASITIC DISEASES BY INHIBITION OF CYSTEINE PROTEASES OF THE PAPAIN SUPERFAMILY | SMITHKLINE BEECHAM CORPORATION (US) | 1999-10-21 | — | — | WO | disclosed |
| EP-0934291-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-08-11 | — | — | EP | disclosed |
| EP-0934938-A1 | SUBSTITUTED BENZOYLAMINOTHIAZOLE DERIVATIVES AND DRUGS CONTAINING THE SAME | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1999-08-11 | — | — | EP | disclosed |
| EP-0934291-A4 | — | SMITHKLINE BEECHAM CORP (US) | 1999-08-11 | — | — | EP | disclosed |
| EP-0928790-A1 | Thiazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-07-14 | — | — | EP | disclosed |
| WO-1998048799-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-11-05 | — | — | WO | disclosed |
| WO-1998049152-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-11-05 | — | — | WO | disclosed |
| WO-1998046582-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-10-22 | — | — | WO | disclosed |
| WO-1997016433-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-05-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11274074-B2 | Pharmaceutical composition for ANO1 antagonist with anticancer activity | ANO1, ANO2, TMEM109 | RAB9A 714/4885MAPT 4557/4885NPC1 191/4885 |
| US-20150038523-A1 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING ALPHA-V-BETA-3 | ITGB3, ITGAV, ITGB1 | RAB9A 1131/4885MAPT 3886/4885NPC1 1531/4885 |
| US-20100261760-A1 | EP2 Receptor Agonists | PTGER2, PTGER1, TBXA2R | RAB9A 3197/4885MAPT 4372/4885NPC1 1845/4885 |
| US-20200087250-A1 | PHARMACEUTICAL COMPOSITION FOR ANO1 ANTAGONIST WITH ANTICANCER ACTIVITY | ANO1, ANO2, TMEM109 | RAB9A 714/4885MAPT 4557/4885NPC1 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.